mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
-0.049 |
0.1 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.05 |
0.1 |
mRNA |
Cytarabine |
GDSC1000 |
pan-cancer |
AAC |
-0.05 |
0.1 |
mRNA |
isonicotinohydroxamic acid |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.1 |
mRNA |
Erlotinib |
CCLE |
pan-cancer |
AAC |
-0.066 |
0.1 |
mRNA |
ruxolitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.047 |
0.1 |
mRNA |
Obatoclax Mesylate |
CTRPv2 |
pan-cancer |
AAC |
-0.05 |
0.1 |
mRNA |
Ki8751 |
CTRPv2 |
pan-cancer |
AAC |
-0.053 |
0.1 |
mRNA |
PF-543 |
CTRPv2 |
pan-cancer |
AAC |
-0.055 |
0.1 |
mRNA |
ibrutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.062 |
0.1 |